What Is the Drug Molly? Effects and Dangers

Molly is a street name for MDMA (3,4-methylenedioxymethamphetamine), a synthetic drug that acts as both a stimulant and a mood-altering substance. The name “Molly” has been used in the United States since the early 2000s to refer specifically to the powder or crystalline form, as distinct from pressed pills typically called “ecstasy,” though in practice the two overlap considerably and neither label guarantees what is actually in the substance.

What MDMA Actually Is

MDMA is an amphetamine derivative that shares some pharmacological properties with mescaline, placing it in an unusual space between stimulants and psychedelics.¹ It was first synthesized in 1912 by the pharmaceutical company Merck, not as a recreational drug but as a chemical intermediate during an attempt to develop a blood-clotting agent.² Its psychoactive properties went unnoticed for decades. Between 1977 and 1985, a small number of American psychotherapists used it legally, prizing what they described as its “benign, feeling-enhancing, and nonhallucinatory properties.”³ The DEA emergency-scheduled MDMA and pushed for international scheduling through the World Health Organization, effectively banning it in the mid-1980s.⁴

Pharmacologists eventually gave MDMA and related compounds their own class name: entactogens. The term was proposed in 1986 to distinguish MDMA from classical hallucinogens, since its molecular structure and psychological effects are genuinely different from drugs like LSD or psilocybin.⁵ The word roughly means “touching within,” a nod to the drug’s characteristic effect of creating feelings of emotional closeness and openness.

How MDMA Works in the Brain

MDMA’s main action is flooding the brain with serotonin, dopamine, and norepinephrine by acting on the transporters that normally recycle these chemicals. Research confirms that MDMA acts on both the dopamine transporter and the serotonin transporter, raising the levels of both chemicals outside the cell.⁶ The serotonin surge is the dominant one, and it accounts for much of MDMA’s emotional character: the warmth, empathy, and desire for social connection that users describe.

On top of the serotonin flood, MDMA triggers a large release of oxytocin, sometimes called the “bonding hormone.” One study found that the drug caused a robust increase in blood oxytocin levels, and that variations in prosocial feelings tracked more closely with oxytocin changes than with blood MDMA concentrations themselves.⁷ This oxytocin spike helps explain why MDMA does not feel like a typical stimulant: instead of aggression or jitteriness, users tend to report emotional warmth and a sense of connection. That same oxytocin release, however, also plays a role in one of the drug’s serious medical dangers, as discussed below.

Acute Effects on Mind and Body

The psychological experience of MDMA typically includes heightened empathy, emotional openness, euphoria, and increased sensory pleasure, particularly with music and touch. These effects usually begin within 30 to 60 minutes of ingestion and last roughly three to five hours.

On the physical side, the most common complaints during a controlled MDMA session are jaw clenching, loss of appetite, impaired coordination, and restless legs.⁸ MDMA moderately raises blood pressure and heart rate and slightly elevates body temperature.⁹ For most people in a calm setting, these changes are manageable. But research on MDMA-naïve volunteers found that even at a standard recreational dose, one subject had a transient hypertensive reaction severe enough that researchers concluded the cardiovascular effects of MDMA “should not be underestimated, particularly in subjects with latent cardiovascular problems.”⁸ In other words, an unknown heart condition and MDMA are a dangerous combination.

The Purity Problem

One of the most underappreciated dangers of Molly is that you often have no idea what you are actually taking. Many people assume that “Molly” in powder or crystal form is purer than pressed ecstasy pills, but research directly contradicts this. A study analyzing 529 samples found MDMA in only about 60% of them, with no significant difference in purity between products sold as “Ecstasy” and those sold as “Molly.”¹⁰ The remaining samples contained other substances, often ones the buyer had no intention of taking.

Researchers have raised concern that Molly is so frequently adulterated with novel psychoactive substances, including synthetic cathinones (commonly called “bath salts”), that the street name may no longer meaningfully represent MDMA at all.¹¹ This matters enormously for safety: the physiological risks of unknown substitutes can be wildly different from those of MDMA itself, and a user who thinks they are taking a known substance may not recognize the symptoms of something far more dangerous.

Serious Medical Dangers

The acute dangers of MDMA go well beyond a racing heart. Three medical emergencies stand out as the most threatening.

Hyperthermia

MDMA disrupts the body’s ability to regulate temperature in two ways at once: it increases metabolic heat production and it impairs the body’s normal cooling mechanisms. The onset of sweating is delayed, and blood vessels near the skin constrict rather than dilate, trapping heat inside.¹² This effect is driven partly by MDMA-triggered norepinephrine release, which ramps up heat generation while simultaneously cutting off heat dissipation through the skin.¹³ In a hot, crowded environment like a nightclub or outdoor festival, where the body is already struggling to cool itself, this can spiral into life-threatening hyperthermia with core temperatures climbing above 40°C (104°F). Organ failure and death can follow.

Hyponatremia

Perhaps less well known is the risk of dangerously low sodium levels, a condition called hyponatremia. MDMA triggers a large release of oxytocin, and analysis of clinical trial data showed that the spike in oxytocin was negatively correlated with changes in blood sodium levels: the higher the oxytocin went, the more sodium dropped.¹⁴ The mechanism involves MDMA stimulating the release of antidiuretic hormone, which causes the body to retain water. When a person then drinks large amounts of fluid, as is common at dance events where overheating is a worry, blood sodium can plummet.¹⁵ Severe hyponatremia can cause brain swelling, seizures, and death.

There is a cruel irony in this: people who have heard about MDMA’s overheating risk sometimes try to counteract it by drinking excessive water, which can actually trigger the opposite lethal problem. Sipping small amounts regularly is safer than gulping large volumes.

Serotonin Syndrome

Because MDMA massively increases serotonin activity, combining it with other substances that affect serotonin can push the system into a dangerous overdrive known as serotonin syndrome. This is especially relevant for anyone taking SSRI antidepressants, which are among the most widely prescribed medications worldwide. MDMA combined with an SSRI can cause a rapid, synergistic rise in serotonin in the central nervous system, producing the medical emergency.¹⁶ Symptoms can range from agitation and tremors to muscle rigidity, high fever, and organ failure.

Interestingly, a review of reported serotonin syndrome cases in a federal adverse-event database found that all 20 cases involving MDMA also involved at least one other serotonergic substance. There were no cases where MDMA alone caused the syndrome.¹⁷ This does not mean MDMA is “safe” on its own, but it underscores that the interaction with other drugs, prescription or otherwise, is the primary trigger for this particular emergency.

Why Women Face Higher Risk from Hyponatremia

The risk of severe hyponatremia from MDMA falls disproportionately on women. Women account for more than 80% of reported fatalities from ecstasy-associated hyponatremia.¹⁸ The reasons appear to be hormonal. Estrogen enhances the release of vasopressin (the antidiuretic hormone that MDMA triggers) and also impairs the kidneys’ ability to excrete free water. Together, these effects create a particularly high vulnerability to severe hyponatremia and brain swelling in premenopausal women.¹⁸ This is a risk that gets almost no attention in the settings where MDMA is typically used, and it is not something that can be managed simply by “being careful.”

The Comedown

After the serotonin surge of an MDMA experience, the brain’s supply of available serotonin is temporarily depleted. Most users describe a low period in the days following use, sometimes called “Suicide Tuesday” in British slang (reflecting the typical lag when weekend use leads to a midweek dip). A recent longitudinal study of European nightlife participants found a measurable drop in mental well-being during the three days after MDMA use, even after accounting for other substance use, baseline depression, anxiety, and sleep quality. The effect was specific to MDMA and cocaine; other commonly used substances did not show the same pattern.¹⁹

For most people, this mood dip resolves within a few days to a week. But for someone already dealing with depression or anxiety, the post-MDMA low can be more intense and disorienting than expected. It is worth knowing about in advance, because the sudden emotional crash can feel alarming if you are not prepared for it.

Long-Term Effects on the Brain

The question of whether MDMA causes lasting brain damage has been debated for decades, and the honest answer is that the evidence is suggestive but messy. A major review concluded that despite serious methodological problems across the research, the bulk of evidence points to residual changes in serotonin function in people who use MDMA, though at least partial recovery may occur after long-term abstinence.²⁰

The most consistent finding is an association between heavy ecstasy use and subtle memory impairments. Research on abstinent MDMA users found that greater cumulative use was linked to worse performance on tests of immediate verbal memory and delayed visual memory, and that lower serotonin metabolite levels in spinal fluid were associated with poorer memory scores.²¹ The word “subtle” matters here: these are not dramatic cognitive collapses but detectable deficits on neuropsychological tests, and they are most clearly seen in heavy, repeated users rather than someone who tried the drug once or twice. Still, the evidence is strong enough that “MDMA is harmless” is not a defensible claim.

Can You Get Addicted?

MDMA is generally described as having low addiction potential, and this is roughly true compared to substances like opioids, nicotine, or methamphetamine. Most users do not escalate to daily use, partly because the drug stops working well with frequent dosing as serotonin stores deplete. However, “low potential” does not mean “zero potential.” Case reports have documented individuals who met clinical criteria for dependence on MDMA, including compulsive use, continued use despite harmful consequences, and difficulty stopping.²² These cases are rare, but they are worth acknowledging because very heavy use may compound the serotonin-related neuronal changes discussed above.

Drug Checking and Its Limits

Given the adulteration problem, some harm-reduction organizations offer drug checking at festivals and events. The most accessible tool is the colorimetric reagent test kit, which involves dropping a chemical reagent onto a small sample and watching for a color change. These kits can indicate whether MDMA is likely present, and research shows that people are significantly less likely to take a substance if the test does not identify MDMA as an ingredient.¹⁰

But these kits have real limitations. A study testing common reagent kits (Marquis, Mecke, and Simon’s) found that they could not differentiate pure MDMA from adulterated forms, and both novice users and experienced toxicologists produced false-positive results.²³ A positive color change tells you MDMA is probably present, but it does not tell you what else might be mixed in. Fentanyl test strips add another layer of checking and are increasingly available, though festival attendees report various barriers to using either tool, including difficulty accessing the materials, legal concerns, social pressure, and the practical challenge of doing careful chemistry in a loud, crowded field.²⁴

Drug checking is better than nothing, and evidence supports it as a legitimate harm-reduction measure. But it is not a guarantee of safety, and treating a positive reagent test as proof of purity is a mistake.

MDMA in Therapeutic Research

The same properties that make MDMA appealing recreationally, its ability to reduce fear, increase emotional openness, and promote trust, have drawn serious clinical interest for treating post-traumatic stress disorder. MDMA-assisted psychotherapy received a “breakthrough therapy” designation from the FDA, a label reserved for treatments that show substantial improvement over existing options.²⁵

A phase 3 trial published in Nature Medicine found that MDMA-assisted therapy significantly reduced PTSD symptoms compared to therapy with a placebo, with a moderate-to-large effect size. The treatment also improved functional impairment, meaning people were better able to manage daily life. Nearly all participants experienced at least one side effect during the study, but none experienced a serious treatment-related adverse event.²⁶ A subsequent meta-analysis pooling data across nine studies also found a reduction in PTSD symptom severity associated with MDMA-assisted therapy, though it flagged that most of the underlying studies had a high risk of bias in outcome measurement, and the overall certainty of the evidence was rated very low.²⁷

The FDA ultimately declined to approve MDMA-assisted therapy in 2024, citing concerns about trial methodology and the difficulty of blinding participants (most people can tell whether they received MDMA or a placebo, which complicates the interpretation of results). Research continues, but the path from “promising trial results” to “approved medicine” has proven more complicated than early enthusiasm suggested. It is worth emphasizing that therapeutic MDMA use, if it ever becomes available, would involve carefully controlled doses in a clinical setting with trained therapists. It has essentially nothing in common with taking an unknown powder at a music festival.

Who Uses Molly and How Common Is It

National survey data from the United States estimates that about 0.9% of people aged 12 and older used ecstasy or MDMA in the past year. Use is highest among young adults aged 18 to 34 and drops sharply after 50.²⁸ Researchers have noted, however, that these figures likely undercount actual use because many surveys do not include the word “Molly” alongside “ecstasy” or “MDMA,” and some users do not recognize the older terms.¹¹ The drug remains strongly associated with electronic music events, nightclubs, and festival culture, though its use is not confined to those settings.

1
PubMed Central. The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs
2
The History of MDMA. The Early History of MDMA
3
Drug Science, Policy and Law. The early use of MDMA (‘Ecstasy’) in psychotherapy (1977–1985)
4
The History of MDMA. The Scheduling
5
Frontiers in Psychiatry. Entactogens: How the Name for a Novel Class of Psychoactive Agents Originated
6
PubMed Central. Effects of MDMA on Extracellular Dopamine and Serotonin Levels in Mice Lacking Dopamine and/or Serotonin Transporters
7
PubMed. Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration
8
Neuropsychopharmacology. Psychological and Cardiovascular Effects and Short-Term Sequelae of MDMA (“Ecstasy”) in MDMA-Naïve Healthy Volunteers
9
PubMed. The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine (‘Ecstasy’) in healthy volunteers
10
PubMed. Who is ‘Molly’? MDMA adulterants by product name and the impact of harm-reduction services at raves
11
PubMed Central. There’s something about Molly: The underresearched yet popular powder form of ecstasy in the United States
12
Drug and Alcohol Dependence. MDMA and temperature: A review of the thermal effects of ‘Ecstasy’ in humans
13
PubMed Central. Effects of MDMA on body temperature in humans
14
JAMA Network Open. Oxytocin and the Role of Fluid Restriction in MDMA-Induced Hyponatremia: A Secondary Analysis of 4 Randomized Clinical Trials
15
PubMed Central. SIADH and water intoxication related to ecstasy
16
PubMed. Ecstasy use and serotonin syndrome: a neglected danger to adolescents and young adults prescribed selective serotonin reuptake inhibitors
17
PubMed Central. Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database
18
PubMed Central. Ecstacy-associated hyponatremia: why are women at risk?
19
Drug and Alcohol Dependence. Three-day blues after ecstasy/MDMA use: Evidence from a longitudinal and daily analysis in the European nightlife scene
20
PubMed. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?
21
PubMed. Memory impairment in abstinent MDMA (“Ecstasy”) users
22
PubMed. Ecstasy (MDMA) dependence
23
PubMed. Putting an Ecstasy test kit to the test: harm reduction or harm induction?
24
PubMed Central. Use of reagent test kits and fentanyl test strips among electronic music festival attendees in Colorado: prevalence, barriers, and behavior in response to drug checking
25
PubMed Central. MDMA-Based Psychotherapy in Treatment-Resistant Post-Traumatic Stress Disorder (PTSD): A Brief Narrative Overview of Current Evidence
26
Nature Medicine. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial
27
European Neuropsychopharmacology. Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder: A systematic review and meta-analysis of clinical and functional outcomes
28
PubMed Central. Prevalence and Correlates of Past-Year Ecstasy/MDMA Use in the United States